ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients.

J. Fose,1 E. McCreary,1 M. Jorgenson,1 M. Lucey,2 J. Smith.2

1Pharmacy, University of Wisconsin Hospital and Clinics, Madison, WI
2Medicine, University of Wisconsin Hospital and Clinics, Madison, WI

Meeting: 2017 American Transplant Congress

Abstract number: A283

Keywords: Cytomeglovirus, Liver transplantation, Prophylaxis

Session Information

Session Name: Poster Session A: Viral Conundrums

Session Type: Poster Session

Date: Saturday, April 29, 2017

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Purpose: Evaluate the incidence of cytomegalovirus (CMV) infection in seropositive (R+) solid organ transplant recipients (SOT) receiving high-dose acyclovir (HD-A, 800 mg QID) prophylaxis.

Methods: Retrospective single-center study of R+ adult SOT transplanted without lymphocyte-depleting induction between 1/1/2000-6/30/2013 prescribed 3 months of HD-A prophylaxis at time of hospital discharge. Primary outcome was incidence of prophylaxis failure overall, defined as any CMV infection during the prophylactic period. Secondary outcomes included overall incidence of biopsy-proven tissue invasive disease (TIDx) and subgroup analyses by allograft type.

Results: A total of 1525 transplant recipients met inclusion criteria: 944 renal (RTX), 108 simultaneous pancreas-kidney (SPK), 462 liver (LTX), and 11 pancreas (PTA). During the prophylactic period overall rate of prophylaxis failure was 7% and overall rate of TIDx was 0.4%. On subgroup analysis rate of failure in the RTX population was 4.5% overall with 0.2% incidence of TIDx, SPK – 6.1% overall with no TIDx, LTX -11% overall with 0.7% TIDx and PTA – 20% overall with 10% TIDx. Failure occurred at a statistically significantly higher rate in the LTX population then the RTX population (p=<0.0001, HR 2.6), Incidence of TIDx was minimal and not significantly different between groups (p=0.34). In order to elucidate risk factors associated with failure in the population most likely to benefit from alternative prophylactic schemes (LTX) a multivariable analysis was conducted. CMV donor negativity was associated with a decreased risk of failure (p<0.0001, HR 0.176). Mechanical ventilation increased risk of failure by 1.05 for each week received post-operatively (p=0.04).

Conclusions: In this single center cohort there was a measurable incidence of CMV infection during the 3 month prophylactic period with HD-A. Breakthrough CMV appears to be limited to viremia. In the LTX subgroup donor seronegativity had a protective effect against failure while increasing ventilation time increased risk. Overall, HD-A does not appear to be an appropriate prophylactic modality; however investigation of its use in recipients of CMV seronegative liver allografts is warranted due to known tolerance issues with the standard of care in this population.

CITATION INFORMATION: Fose J, McCreary E, Jorgenson M, Lucey M, Smith J. High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Fose J, McCreary E, Jorgenson M, Lucey M, Smith J. High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/high-dose-acyclovir-for-cytomegalovirus-prevention-in-seropositive-solid-organ-transplant-recipients/. Accessed May 9, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences